Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jussi P. Pärkkä is active.

Publication


Featured researches published by Jussi P. Pärkkä.


The Journal of Clinical Endocrinology and Metabolism | 2009

Contribution of Glucose Tolerance and Gender to Cardiac Adiposity

Riikka Lautamäki; Ronald Borra; Hanna-Riikka Lehto; Marco Bucci; Antti Viljanen; Jussi P. Pärkkä; Virva Lepomäki; Romina Maggio; Riitta Parkkola; Juhani Knuuti; Pirjo Nuutila

CONTEXT AND OBJECTIVE To examine whether pericardial and myocardial fat depots may contribute to the association between diabetes and cardiovascular risk, including sex-related differences, and the role of adiponectin, we evaluated data in patients with obesity and without diabetes [nondiabetic (ND)] or with impaired glucose tolerance or type 2 diabetes and in lean ND controls. METHODS Magnetic resonance imaging and spectroscopy were used to measure left ventricular (LV) function and abdominal sc and visceral fat areas to estimate respective masses, pericardial fat depots, and myocardial triglyceride content in 53 subjects (10 lean ND, 25 obese ND, six impaired-glucose-tolerance, and 12 type 2 diabetic patients with macrovascular disease); gender effects and adiponectin levels were evaluated in the available subset of subjects. RESULTS Myocardial and pericardial fat increased progressively across study groups. They were lower in obese women than men (P = 0.002), but cardiac steatosis caught up in hyperglycemic women (+81% vs. ND, P = 0.01). Adiponectin was inversely related with both fat depots (P < 0.01) and LV mass (P = 0.003) and positively with LV function (P = 0.03). In multiple regression analysis, myocardial and pericardial fat were independently related with plasma glucose levels, only pericardial fat mass was associated with visceral adiposity and myocardial fat with cardiac output and work. CONCLUSIONS We conclude that glycemia, gender, adiponectin, and cardiac workload are associated with, and hyperglycemia and male gender are independent positive predictors of, heart adiposity. Once glucose tolerance becomes impaired, the evolution of cardiac steatosis is more pronounced in women.


American Journal of Cardiology | 2009

Effect of Caloric Restriction on Myocardial Fatty Acid Uptake, Left Ventricular Mass, and Cardiac Work in Obese Adults

Antti Viljanen; Anna Karmi; Ronald Borra; Jussi P. Pärkkä; Virva Lepomäki; Riitta Parkkola; Riikka Lautamäki; Mikko J. Järvisalo; Markku Taittonen; Tapani Rönnemaa; Juhani Knuuti; Pirjo Nuutila; Olli T. Raitakari

Obesity is associated with increased fatty acid uptake in the myocardium, and this may have deleterious effects on cardiac function. The aim of this study was to evaluate how weight loss influences myocardial metabolism and cardiac work in obese adults. Thirty-four obese (mean body mass index 33.7 +/- 0.7 kg/m(2)) but otherwise healthy subjects consumed a very low calorie diet for 6 weeks. Cardiac substrate metabolism and work were measured before and after the diet. Myocardial fatty acid uptake was measured in 18 subjects using fluorine-18-fluoro-6-thia-heptadecanoic acid and positron emission tomography, and myocardial glucose uptake was measured in 16 subjects using fluorine-18-2-fluoro-2-deoxyglucose. Myocardial structure and cardiac function were measured using magnetic resonance imaging. Consumption of the very low calorie diet decreased weight (-11.2 +/- 0.6 kg, p <0.0001). Myocardial fatty acid uptake decreased from 4.2 +/- 0.4 to 2.9 +/- 0.2 micromol/100 g/min (p <0.0001). Myocardial mass decreased by 7% (p <0.005), and cardiac work decreased by 26% (p <0.0001). Whole-body insulin sensitivity increased by 33% (p <0.01), but insulin-stimulated myocardial glucose uptake remained unchanged (p = 0.90). Myocardial triglyceride content decreased by 31% (n = 8, p = 0.076). In conclusion, weight reduction decreases myocardial fatty acid uptake in parallel with myocardial mass and cardiac work. These results show that the increased fatty acid uptake found in the hearts of obese patients can be reversed by weight loss.


Magnetic Resonance in Medicine | 2006

Comparison of MRI and positron emission tomography for measuring myocardial perfusion reserve in healthy humans

Jussi P. Pärkkä; Pekka Niemi; Antti Saraste; Juha W. Koskenvuo; Markku Komu; Vesa Oikonen; Jyri Toikka; Tuomas Kiviniemi; Juhani Knuuti; Hajime Sakuma; Jaakko Hartiala

Myocardial perfusion reserve (MPR, defined as the ratio of the maximum myocardial blood flow (MBF) to the baseline) is an indicator of coronary artery disease and myocardial microvascular abnormalities. First‐pass contrast‐enhanced magnetic resonance imaging (CE‐MRI) using gadolinium (Gd)‐DTPA as a contrast agent (CA) has been used to assess MPR. Tracer kinetic models based on compartmental analysis of the CA uptake have been developed to provide quantitative measures of MBF by MRI. To study the accuracy of Gd‐DTPA first‐pass MRI and kinetic modeling for quantitative analysis of myocardial perfusion and MPR during dipyridamole infusion, we conducted a comparison with positron emission tomography (PET) in 18 healthy males (age = 40 ± 14 years). Five planes were acquired at every second heartbeat with a 1.5T scanner using a saturation recovery turboFLASH sequence. A perfusion‐related parameter, the unidirectional influx constant (Ki), was computed in three coronary artery territories. There was a significant correlation for both dipyridamole‐induced flow (0.70, P = 0.001) and MPR (0.48, P = 0.04) between MRI and PET. However, we noticed that MRI provided lower MPR values compared to PET (2.5 ± 1.0 vs. 4.3 ± 1.8). We conclude that MRI supplemented with tracer kinetic modeling can be used to quantify myocardial perfusion. Magn Reson Med, 2006.


Cardiovascular Therapeutics | 2012

Trimetazidine reduces endogenous free fatty acid oxidation and improves myocardial efficiency in obese humans.

Marco Bucci; Ronald Borra; Kjell Någren; Jussi P. Pärkkä; Silvia Del Ry; Romina Maggio; Helena Tuunanen; Tapio Viljanen; Manuela Cabiati; Sara Rigazio; Markku Taittonen; Uberto Pagotto; Riitta Parkkola; Lionel H. Opie; Pirjo Nuutila; Juhani Knuuti

INTRODUCTION The metabolic modulator trimetazidine (TMZ) has been suggested to induce a metabolic shift from myocardial fatty acid oxidation (FAO) to glucose utilization, but this mechanism remains unproven in humans. The oxidation of plasma derived FA is commonly measured in humans, whereas the contribution of FA from triglycerides stored in the myocardium has been poorly characterized. AIMS To verify the hypothesis that TMZ induces a metabolic shift, we combined positron emission tomography (PET) and magnetic resonance spectroscopy ((1)H-MRS) to measure myocardial FAO from plasma and intracellular lipids, and myocardial glucose metabolism. Nine obese subjects were studied before and after 1 month of TMZ treatment. Myocardial glucose and FA metabolism were assessed by PET with (18)F-fluorodeoxyglucose and (11)C-palmitate. (1)H-MRS was used to measure myocardial lipids, the latter being integrated into the PET data analysis to quantify myocardial triglyceride turnover. RESULTS Myocardial FAO derived from intracellular lipids was at least equal to that of plasma FAs (P = NS). BMI and cardiac work were positively associated with the oxidation of plasma derived FA (P ≤ 0.01). TMZ halved total and triglyceride-derived myocardial FAO (32.7 ± 8.0 to 19.6 ± 4.0 μmol/min and 23.7 ± 7.5 to 10.3 ± 2.7 μmol/min, respectively; P ≤ 0.05). These changes were accompanied by increased cardiac efficiency since unchanged LV work (1.6 ± 0.2 to 1.6 ± 0.1 Watt/g × 10(2), NS) was associated with decreased work energy from the intramyocardial triglyceride oxidation (1.6 ± 0.5 to 0.4 ± 0.1 Watt/g × 10(2), P = 0.036). CONCLUSIONS In obese subjects, we demonstrate that myocardial intracellular triglyceride oxidation significantly provides FA-derived energy for mechanical work. TMZ reduced the oxidation of triglyceride-derived myocardial FAs improving myocardial efficiency.


Clinical Physiology and Functional Imaging | 2007

Cardiac MRI: accuracy of simultaneous measurement of left and right ventricular parameters using three different sequences.

Juha W. Koskenvuo; Henna Karra; Jaakko Lehtinen; Pekka Niemi; Jussi P. Pärkkä; Juhani Knuuti; Jaakko Hartiala

Background and aim:  We evaluated a value of Qp/Qs (left‐to‐right shunt measurement) using volumetric cardiac magnetic resonance (CMR) cardiac output (CO) measurements. We defined intraobserver, interobserver variability and reproducibility of left and right ventricular parameters by CMR. Furthermore, we studied whether shortened acquisition time has an effect on the accuracy of left and right ventricular parameters both in healthy volunteers and in patients with cardiovascular disease.


The Journal of Clinical Endocrinology and Metabolism | 2012

Effects of Acute and One-Week Fatty Acid Lowering on Cardiac Function and Insulin Sensitivity in Relation with Myocardial and Muscle Fat and Adiponectin Levels

Hanna-Riikka Lehto; Jussi P. Pärkkä; Ronald Borra; Helena Tuunanen; Virva Lepomäki; Riitta Parkkola; Juhani Knuuti; Pirjo Nuutila

BACKGROUND/AIM We tested the hypothesis that a persistent reduction in free fatty acid (FFA) levels improves cardiac function and systemic insulin sensitivity via a reduction in the myocardial and skeletal muscle adiposities and a modulation in adipokine release. METHODS Study subjects (body mass index 22-30 kg/m(2), 57 ± 3 yr old) underwent magnetic resonance imaging and spectroscopy to measure the cardiac function and the amounts of fat inside and around the myocardium and skeletal muscle, before (n = 10) and after acute (n = 8) and 1 wk (n = 7, one excluded from analysis) lowering of circulating FFA by acipimox. Circulating adipokines (leptin, adiponectin, resistin, TNFα, IL-6, IL-8, plasminogen activator inhibitor-I, macrophage chemoattractant protein-1) were measured. RESULTS The ejection fraction (62 ± 2 vs. 56 ± 1%, P = 0.0035), cardiac output (6.6 ± 0.3 vs. 5.5 ± 0.2 liters/min, P = 0.0018), and forward work (708 ± 49 vs. 539 ± 44 mm Hg × liters/min, P = 0.018) were significantly lower after 1 wk of FFA lowering. In the six subjects undergoing all sessions, the stroke and end-diastolic volumes were also reduced, insulin sensitivity was increased by 33%, and adiponectinemia was decreased (-26%, P = 0.03). No change in intracellular cardiac and skeletal muscle triglyceride levels was observed. Metabolic changes correlated with the lowering of FFA. The reduction in cardiac function was related with changes in glycemia and insulin sensitivity, whereas the deflection in left ventricular work was correlated with the decline in FFA, lipid, and blood pressure levels. CONCLUSIONS A 1-wk FFA depletion suppressed cardiac function and improved insulin sensitivity. Intracellular triglyceride deposits in the heart and skeletal muscle played no role in the observed changes. Our data show that FFA participate in the physiological regulation of adipokine levels.


Heart | 2007

Coronary Artery Flow Velocity Profile Measured by Transthoracic Doppler Echocardiography Predicts Myocardial Viability After Acute Myocardial Infarction

Antti Saraste; Juha W. Koskenvuo; Markku Saraste; Jussi P. Pärkkä; Jyri Toikka; Alexandru Naum; Heikki Ukkonen; Juhani Knuuti; Juhani Airaksinen; Jaakko Hartiala

Objective: To study whether flow velocity profile in the left anterior descending coronary artery (LAD) measured by transthoracic Doppler echocardiography (TTDE) predicts myocardial viability after reperfused anterior acute myocardial infarction (AMI). Patients and methods: 15 patients who had their first anterior ST elevation AMI and were successfully reperfused by coronary angioplasty and five controls without coronary artery disease were selected. Blood flow velocity spectrum was measured from the mid-LAD by TTDE 3 days after coronary angioplasty. Myocardial viability in the LAD region was quantified 3 months after AMI by relative uptake of 18F-fluorodeoxyglucose (FDG) imaged with positron emission tomography. Myocardium was graded as viable, partially viable or non-viable (relative FDG uptake >85%, 67–85% and <67%, respectively). Main outcome measures were diastolic deceleration time (DDT) of LAD flow velocity 3 days after AMI and myocardial viability 3 months after AMI. Results: DDT of LAD flow velocity correlated with myocardial FDG uptake in the LAD region (r = 0.91, p<0.01). DDT was markedly longer in patients with viable myocardium (876±76 ms, n = 3) than partially viable (356±89 ms, n = 6, p<0.01), or non-viable myocardium (128±13 ms, n = 6, p<0.01). In controls, DDT was comparable (909±76 ms, n = 5) to patients with viable myocardium. DDT <190 ms was always associated with non-viable myocardium. Conclusions: DDT of LAD flow velocity is strongly associated with myocardial viability after reperfused anterior AMI. Non-invasive TTDE of the LAD may be used in the acute phase to predict long-term viability of the jeopardised myocardium.


The Journal of Physiology | 2016

Left ventricular vascular and metabolic adaptations to high-intensity interval and moderate intensity continuous training: a randomized trial in healthy middle-aged men

Jari-Joonas Eskelinen; Ilkka Heinonen; Eliisa Löyttyniemi; Juuso Hakala; Marja A. Heiskanen; Kumail K. Motiani; Kirsi A. Virtanen; Jussi P. Pärkkä; Juhani Knuuti; Jarna C. Hannukainen; Kari K. Kalliokoski

High‐intensity interval training (HIIT) has become popular, time‐sparing alternative to moderate intensity continuous training (MICT), although the cardiac vascular and metabolic effects of HIIT are incompletely known. We compared the effects of 2‐week interventions with HIIT and MICT on myocardial perfusion and free fatty acid and glucose uptake. Insulin‐stimulated myocardial glucose uptake was decreased by training without any significantly different response between the groups, whereas free fatty acid uptake remained unchanged. Adenosine‐stimulated myocardial perfusion responded differently to the training modes (change in mean HIIT: –19%; MICT: +9%; P = 0.03 for interaction) and was correlated with myocardial glucose uptake for the entire dataset and especially after HIIT training. HIIT and MICT induce similar metabolic and functional changes in the heart, although myocardial vascular hyperaemic reactivity is impaired after HIIT, and this should be considered when prescribing very intense HIIT for previously untrained subjects.


Frontiers in Physiology | 2012

Cardiac function, perfusion, metabolism, and innervation following autologous stem cell therapy for acute ST-elevation myocardial infarction. A FINCELL-INSIGHT sub-study with PET and MRI

Maija Mäki; Juha W. Koskenvuo; Heikki Ukkonen; Antti Saraste; Helena Tuunanen; Mikko Pietilä; Sergey V. Nesterov; Ville Aalto; K.E. Juhani Airaksinen; Jussi P. Pärkkä; Riikka Lautamäki; Kari Kervinen; Johanna A. Miettinen; Timo H. Mäkikallio; Matti Niemelä; Marjaana Säily; Pirjo Koistinen; Eeva-Riitta Savolainen; Kari Ylitalo; Heikki V. Huikuri; Juhani Knuuti

Purpose: Beneficial mechanisms of bone marrow cell (BMC) therapy for acute ST-segment elevation myocardial infarct (STEMI) are largely unknown in humans. Therefore, we evaluated the feasibility of serial positron emission tomography (PET) and MRI studies to provide insight into the effects of BMCs on the healing process of ischemic myocardial damage. Methods: Nineteen patients with successful primary reteplase thrombolysis (mean 2.4 h after symptoms) for STEMI were randomized for BMC therapy (2.9 × 106 CD34+ cells) or placebo after bone marrow aspiration in a double-blind, multi-center study. Three days post-MI, coronary angioplasty, and paclitaxel eluting stent implantation preceded either BMC or placebo therapy. Cardiac PET and MRI studies were performed 7–12 days after therapies and repeated after 6 months, and images were analyzed at a central core laboratory. Results: In BMC-treated patients, there was a decrease in [11C]-HED defect size (−4.9 ± 4.0 vs. −1.6 ± 2.2%, p = 0.08) and an increase in [18F]-FDG uptake in the infarct area at risk (0.06 ± 0.09 vs. −0.05 ± 0.16, p = 0.07) compared to controls, as well as less left ventricular dilatation (−4.4 ± 13.3 vs. 8.0 ± 16.7 mL/m2, p = 0.12) at 6 months follow-up. However, BMC treatment was inferior to placebo in terms of changes in rest perfusion in the area at risk (−0.09 ± 0.17 vs. 0.10 ± 0.17, p = 0.03) and infarct size (0.4 ± 4.2 vs. −5.1 ± 5.9 g, p = 0.047), and no effect was observed on ejection fraction (p = 0.37). Conclusion: After the acute phase of STEMI, BMC therapy showed only minor trends of long-term benefit in patients with rapid successful thrombolysis. There was a trend of more decrease in innervation defect size and enhanced glucose metabolism in the infarct-related myocardium and also a trend of less ventricular dilatation in the BMC-treated group compared to placebo. However, no consistently better outcome was observed in the BMC-treated group compared to placebo.


Clinical Physiology and Functional Imaging | 2009

Cardiac magnetic resonance imaging in valvular heart disease

Juha W. Koskenvuo; Vesa Järvinen; Jussi P. Pärkkä; Tuomas Kiviniemi; Jaakko Hartiala

Cardiac magnetic resonance imaging (CMR) has rapidly gained acceptance as an accurate, reproducible and non‐invasive imaging method for assessment of a wide range of cardiovascular diseases. However, CMR has not been used widely for diagnostic purposes in valvular heart disease (VHD). Unlike echocardiography it has no body habitus‐related limitations and can thus be used to complement echocardiography. It is an especially good alternative for clinical follow‐up in patients with VHD, as it allows accurate measurement of valvular dysfunction and related ventricular burden. Additionally, CMR is an ideal method for evaluating complex congenital heart disease and determining the significance of its components. It can also be used to study the physiological course of valvular dysfunction and response to therapeutic interventions. In this review, we present a basic introduction to CMR methodology, including its advantages and potential problems, and the physiology and quantification in VHD. We also discuss clinical applications of CMR in VHD. Furthermore, we describe how a CMR study statement should be structured in order to increase clinical use of this valuable methodology in cardiology.

Collaboration


Dive into the Jussi P. Pärkkä's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Antti Saraste

Turku University Hospital

View shared research outputs
Top Co-Authors

Avatar

Jaakko Hartiala

Turku University Hospital

View shared research outputs
Top Co-Authors

Avatar

Juhani Knuuti

Turku University Hospital

View shared research outputs
Top Co-Authors

Avatar

Jyri Toikka

Turku University Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jorma Viikari

Turku University Hospital

View shared research outputs
Researchain Logo
Decentralizing Knowledge